1043871-14-2

Upstream product

• 24892-63-5 1-allyloxy-2-iodobenzene 
• 533-58-4 2-Iodophenol 
• 60333-75-7 O-allyl-2-bromophenol 
• 95-56-7 2-hydroxybromobenzene 
• 10292-60-1 2-cyclopropylphenol 

Downstream Products

• 1016161-78-6 C₁₈H₂₉BrOSi 
• 1062617-16-6 1,2-bis(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethyne 
• 1062617-20-2 1,2-bis(3-cyclopropyl-4-(difluoromethoxy)phenyl)ethane-1,2-dione 
• 1062617-13-3 4-bromo-2-cyclopropyl-1-(difluoromethoxy)benzene 
• 749929-58-6 4-Bromo-2-cyclopropyl-1-methoxy-benzene 

Relevant academic research and scientific papers

BIARYL KINASE INHIBITORS

The present disclosure is directed to biaryl compounds of formula (I) which can inhibit AAKl (adaptor associated kinase 1), compositions comprising such compounds and their use for treating e.g. pain, Alzheimer's disease, Parkinson's disease and schizophrenia.

BIARYL KINASE INHIBITORS

The present disclosure is generally directed to compounds which can inhibit AAK1 (adaptor associated kinase 1), compositions comprising such compounds, and methods for inhibiting AAK1.

5H-PYRROLO[3,4-￡>]PYRAZIN-7-AMINE DERIVATIVES INHIBITORS OF BETA-SECRETASE

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β- amyloid angiopathy such as but not limited to cerebral amyloid angiopathy or hereditary cerebral hemorrhage, disorders associated with cognitive impairment such as but not limited to MCI ("mild cognitive impairment"), Alzheimer Disease, memory loss, attention deficit symptoms associated with Alzheimer disease, neurodegeneration associated with diseases such as Alzheimer disease or dementia including dementia of mixed vascular and degenerative origin, pre-senile dementia, senile dementia and dementia associated with Parkinson's disease, progressive supranuclear palsy or cortical basal degeneration.

NEW COMPOUNDS 574

The present invention relates to novel compounds of formula (I) and their pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome,

AMINO-5-[SUBSTITUTED-4-(DIFLUOROMETHOXY)PHENYL]-5- PHENYLIMIDAZOLONE COMPOUNDS AS ?-SECRETASE INHIBITORS

The present invention provides a 2-amino-5-[substituted-4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula (I) The present invention also provides methods for the use thereof to inhibit ?-secretase (BACE) and treat ?-amyloid deposits and neurofibrillary tangles.

Characterization of thyroid hormone receptor α (TRα)-specific analogs with varying inner- and outer-ring substituents

Analogs of the TRα-specific thyromimetic CO23 were synthesized and analyzed in vitro using competitive binding and transactivation assays. Like CO23, all analogs bind to both thyroid hormone receptor subtypes with about the same affinity; however, modification of CO23 by derivatization of the 3′ position of the outer-ring or replacement of the inner-ring iodides with bromides attenuates binding. Despite lacking a preference in binding to TRα, all analogs display TRα-specificity in transactivation assays using U2OS and HeLa cells. At best, several agonists exhibit an approximately 6-12-fold preference in transactivation when tested with TRα in HeLa cells. One analog, CO24, showed in vivo TRα-specific action in a tadpole metamorphosis assay.